Long-Term Outcomes with Sequential Tyrosine Kinase Inhibitors Treatment in Chronic Myeloid Leukemia Patients
Saikhuan Towachiraporna,
Teerachat Punnachet,
Nonthakorn Hantrakun
et al.
Abstract:Objective: Tyrosine kinase inhibitor (TKI) is the standard treatment for chronic myeloid leukemia (CML).In the national list of essential medicines in Thailand, the first, second, and third-line treatments are imatinib, nilotinib, and dasatinib, sequentially, different from the European Leukemia Net guidelines. This study aimed to evaluate the outcomes of CML patients who received sequential treatment with TKI. Methods: This study enrolled CML patients diagnosed between 2008 and 2020 at Chiang Mai University H… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.